In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...

Regulatory ApprovalFormycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® 25.02.2025 / 06:30 CET/CESTThe issuer is solely ...

J&J said it is seeking a preliminary injunction for Samsung Bioepis' close copy of Stelara over an unauthorized sublicense deal with a private label provider, which the drugmaker declined to identify.

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.

Bank Leumi (TASE: LUMI) led the market today, falling 1.02% on the day's biggest trading turnover. Bank Hapoalim (TASE: POLI) fell 1.37%, Mizrahi Tefahot Bank fell 0.53% and Israel Discount Bank (TASE ...

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...

Bank Leumi (TASE: LUMI) led the market today, falling 1.71% on the day's biggest trading turnover. Mizrahi Tefahot Bank fell 2.25%, Bank Hapoalim (TASE: POLI) fell 1.77%, and Israel Discount Bank ...

Bausch Health reported strong Q4 results with a 6.2% Y/Y revenue increase and positive net income, driving a 10% stock rally.

In our analysis, these 12 brokerage accounts stand out as the best choices for stock trading, due to their low fees, strong platforms and quality customer support. Many, or all, of the products ...

Duquesne Family Office's billionaire chief shed a trillion-dollar artificial intelligence (AI) stock in favor of a ...